Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry R Davis

Showing results (81-90 of 185) with videos related to

Pageof 19
Sort By:
Journal of Clinical Hypertension (Greenwich, Conn.)|April 18, 2014
Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialPaul Muntner, Emily B Levitan, Amy I Lynch, et al.
American Journal of Hypertension|January 24, 2018
The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive MedicationsJoshua I Barzilay, Barry R Davis, Sara L Pressel, et al.
Pharmacogenetics and Genomics|July 16, 2008
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT studyAnke-Hilse Maitland-van der Zee, Amy Lynch, Eric Boerwinkle, et al.
Pharmacogenetics and Genomics|August 30, 2014
Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT studyIzel F Sørensen, Ana I Vazquez, Marguerite R Irvin, et al.
Journal of General Internal Medicine|January 30, 2008
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Paul A Heidenreich, Barry R Davis, Jeffrey A Cutler, et al.
Journal of Diabetes and Its Complications|July 22, 2018
Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetesJoshua I Barzilay, Barry R Davis, Alokananda Ghosh, et al.
Clinical Trials (London, England)|August 29, 2013
Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT studyJason T Connor, Bryan R Luce, Kristine R Broglio, et al.
Journal of Human Hypertension|March 11, 2020
Legacy effect of delayed blood pressure lowering drug treatment in middle-aged adults with mildly elevated blood pressure: systematic review and meta-analysisChau L B Ho, Sharon Sanders, Monique Breslin, et al.
The Journal of Nutrition|December 1, 2004
Dietary carotenoids and genetic instability modify bladder cancer riskMatthew B Schabath, H Barton Grossman, George L Delclos, et al.
American Heart Journal|December 19, 2006
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosisPaula T Einhorn, Barry R Davis, Barry M Massie, et al.
Pageof 19

Showing results (81-90 of 185) with videos related to

Sort By:
Pageof 19
Journal of Clinical Hypertension (Greenwich, Conn.)|April 18, 2014
Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialPaul Muntner, Emily B Levitan, Amy I Lynch, et al.
American Journal of Hypertension|January 24, 2018
The Effects of eGFR Change on CVD, Renal, and Mortality Outcomes in a Hypertensive Cohort Treated With 3 Different Antihypertensive MedicationsJoshua I Barzilay, Barry R Davis, Sara L Pressel, et al.
Pharmacogenetics and Genomics|July 16, 2008
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT studyAnke-Hilse Maitland-van der Zee, Amy Lynch, Eric Boerwinkle, et al.
Pharmacogenetics and Genomics|August 30, 2014
Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT studyIzel F Sørensen, Ana I Vazquez, Marguerite R Irvin, et al.
Journal of General Internal Medicine|January 30, 2008
Cost-effectiveness of chlorthalidone, amlodipine, and lisinopril as first-step treatment for patients with hypertension: an analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Paul A Heidenreich, Barry R Davis, Jeffrey A Cutler, et al.
Journal of Diabetes and Its Complications|July 22, 2018
Rapid eGFR change as a determinant of cardiovascular and renal disease outcomes and of mortality in hypertensive adults with and without type 2 diabetesJoshua I Barzilay, Barry R Davis, Alokananda Ghosh, et al.
Clinical Trials (London, England)|August 29, 2013
Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT studyJason T Connor, Bryan R Luce, Kristine R Broglio, et al.
Journal of Human Hypertension|March 11, 2020
Legacy effect of delayed blood pressure lowering drug treatment in middle-aged adults with mildly elevated blood pressure: systematic review and meta-analysisChau L B Ho, Sharon Sanders, Monique Breslin, et al.
The Journal of Nutrition|December 1, 2004
Dietary carotenoids and genetic instability modify bladder cancer riskMatthew B Schabath, H Barton Grossman, George L Delclos, et al.
American Heart Journal|December 19, 2006
The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosisPaula T Einhorn, Barry R Davis, Barry M Massie, et al.
Pageof 19